Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

Executive Summary

• Defence Therapeutics presented new pre‑clinical data on its Accum® ADC platform at the 16th World ADC Conference in San Diego.
• The data demonstrated enhanced intracellular delivery and payload release, suggesting improved potency and therapeutic index for ADCs.
• The company announced plans to expand collaborative and internal testing of Accum® across a broader range of commercial and clinical‑stage ADC constructs.

Key Details

• Presentation delivered by Dr. Maxime Parisotto, Chief Scientific Officer, highlighted how Accum® improves endosomal escape and payload delivery.
• Attendees showed strong interest; discussions continued beyond the scheduled session.
• Company will test Accum® with multiple on‑market and development‑stage ADCs to validate its “plug‑and‑play” capability.
• Dr. Mark Lambermon, Head of Quality and Operations, confirmed engagement with leading industry partners to accelerate evaluations.
• No immediate commercial product or licensing agreements were announced; the update is forward‑looking regarding future collaborations and validation studies.

Notable Quotes

“The response to our new data was phenomenal… Accum® addresses one of the key challenges in ADC design—efficient endosomal escape and payload delivery.” – Dr. Maxime Parisotto, CSO

“Our goal is to demonstrate that Accum® can universally enhance the performance of ADCs, regardless of the payload or antibody used.” – Dr. Mark Lambermon, Head of Quality and Operations